GlassScriptPhysician profile
Eric Paul Sager
NPI 1841856374
$2,098.71
in general payments reported to CMS, 2019-2025
24 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $428 · 2024: $1,062 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $273.29 | 2023-2025 | |
| Glaxosmithkline, LLC. | $252.78 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $225.73 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $196.47 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $195.96 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $166.06 | 2023-2025 | |
| Lilly USA, LLC | $156.61 | 2023-2024 | Mounjaro |
| Abbvie INC. | $143.12 | 2023-2025 | Mavyret |
| Merck Sharp & Dohme LLC | $125.26 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Insulet Corporation | $53.08 | 2025 | Omnipod |
| Boston Scientific Corporation | $38.26 | 2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $36.54 | 2024-2025 | Farxiga |
| Corium, LLC | $34.11 | 2024 | Azstarys |
| Exeltis, USA INC. | $29.70 | 2024 | Slynd |
| Alkermes, INC. | $26.60 | 2024 | Vivitrol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $24.10 | 2024 | Aptima |
| Otsuka America Pharmaceutical, INC. | $18.82 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $16.78 | 2025 | Nuzyra |
| Integra Lifesciences Corporation | $15.75 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Dexcom, INC. | $15.74 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $13.71 | 2023 | Nexplanon, Nuvaring |
| Teva Pharmaceuticals USA, INC. | $13.65 | 2023 | Austedo |
| Amgen INC. | $13.50 | 2025 | Repatha, Otezla |
| Cumberland Pharmaceuticals, INC. | $13.09 | 2024 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.